Medicine availability and prices in both public and private sectors are key indicators of
access to treatment. Surveys of medicine prices and availability, conducted using a standard …

Objective Compare the utilisation of losartan before and after the availability of generics in
Belgium and its inclusion in the reference price system, which changed its reimbursement …

Background Policy-makers can use a menu of pharmaceutical policy options. This study
aimed to survey these measures that were implemented in European countries between …

Background Healthcare systems spend considerable proportions of their budgets on
pharmaceutical treatment of hypertension, hyperlipidemia, and diabetes mellitus. From data …

Objectives: The current study aims to analyze, from a historical perspective, the regulatory
framework of prices and reimbursement in Bulgaria with emphasis on the introduction of …

Background Cardiovascular diseases are the leading cause of death in Lebanon and Qatar.
When lifestyle modifications prove insufficient, medication becomes a cornerstone in …

BACKGROUND: Managing expenditures on pharmaceuticals is important for health systems
to sustain universal access to necessary medicines. We sought to estimate the size and …

Background There has been an appreciable increase in the prescribing efficiency of proton
pump inhibitors, statins, and renin–angiotensin inhibitor drugs in Sweden in recent years …

ABSTRACT Introduction: The Australian Pharmaceutical Benefits Scheme (PBS) provides
universal access to subsidized medicines. In 2013, statins as a class had the highest …

Managing drug use in a way that maximizes the value obtained from total health care
spending faces obstacles; hence, payers and policymakers tend to look at pharmaceutical …